Showing 1 - 10 of 36 Nervous System Diseases & Disorders
18F-MK-6240 Tau PET and Brain Inflammation in Alzheimer’s Disease

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Nilene Crisci

Phone: 713.441.3771

To clarify the role of inflammation in the pathogenesis of AD, it is important to measure inflammation in brain of people with AD and its relationship with abnormal tau, as the disease progresses. So far, there is no in vivo data in humans verif ... Read more >

A Phase I Trial to Evaluate Safety and Tolerability of Abatacept followed by Subcutaneous Interleukin-2 Administration in Patients with Amyotrophic Lateral Sclerosis

Status: Enrolling

Investigator: Sheetal Shroff

Study Coordinator: KaDeesia Brown

Phone: 713.441.9120

In Amyotrophic Lateral Sclerosis (ALS), the reduction of regulatory T lymphocyte (Treg) numbers and suppressive function correlates with rapid disease progression. We completed a phase 1 study of infusions of expanded autologous Tregs in combina ... Read more >

A Phase IIa randomized, double-blind, placebo-controlled study of the effects of L-serine on Mild Cognitive Impairment (MCI)

Status: Enrolling

Investigator: Gustavo Roman

Study Coordinator: Edwin Vega Vargas

Phone: 713.443.2044

This is a Phase IIa, randomized, double-blinded, placebo-controlled trial to determine the tolerability of L-serine for Mild Cognitive Impairment patients and assess preliminary indications of efficacy. Efficacy will be assessed by cognitive tes ... Read more >

A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects With Spinocerebellar Ataxia.

Status: Enrolling

Investigator: Andrew Billnitzer

Study Coordinator:

Phone:

The purpose of this study is to compare the efficacy of Troriluzole (200mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA). ... Read more >

A prospective, multi-center, observational study of the safety, tolerability and effectiveness of SPINRAZA in adult patients with Spinal Muscular Atr

Status: Open Not Enrolling

Investigator: Bing Liao

Study Coordinator: Anjana Singh

Phone: 713.441.9120

The purpose of this study is to measure the safety and effectiveness of Spinraza in adults with SMA. ... Read more >

A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) (REGENERATE-PD)

Status: Enrolling

Investigator: William Ondo

Study Coordinator: Daniel Arnaud Dominguez

Phone: 346.356.3635

The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease. ... Read more >

A Study of Biological Markers for the Nervous and Immune Systems and Free Radical Mediated Processes in Amyotrophic Lateral Sclerosis (ALS)

Status: Enrolling

Investigator: Stanley Appel

Study Coordinator: KaDeesia Brown

Phone: 713.441.9120

The purpose of this protocol is to develop and maintain a biospecimen bank comprised of blood, urine, CSF collected during diagnostic evaluations, tissue from biopsies and autopsies collected from patients with neurological disease and non-neu ... Read more >

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

Status: Enrolling

Investigator: Juan Toledo Atucha

Study Coordinator: Reena Boradia

Phone: 713.441.1150

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administere ... Read more >

A Study to Perform Apheresis (Leukapheresis) on Patients with Amyotrophic Lateral Sclerosis to Collect Regulatory T-Lymphocytes (Tregs)

Status: Enrolling

Investigator: Sheetal Shroff

Study Coordinator:

Phone:

This leukapheresis study proposes to continue our work in developing and optimizing our Treg manufacturing process. Under this study, up to 10 patients with ALS will undergo leukapheresis. Their Tregs will subsequently be isolated and expand ... Read more >

AC-058B201 Echocardiographic Ancillary Study

Status: Open Not Enrolling

Investigator: Sherif Nagueh

Study Coordinator: Nirali Patel

Phone: 713.441.2116

Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting ... Read more >

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

Status: Enrolling

Investigator: Juan Toledo Atucha

Study Coordinator: David De Leon Garza

Phone: 346.238.1555

The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine w ... Read more >

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

Status: Enrolling

Investigator: Maria Pascual

Study Coordinator: Victoria Arbones

Phone: 713.441.7650

The ARTFL LEFFTDS Longitudinal Frontotemporal Dementia (ALLFTD) study aims to evaluate sporadic (s-) and familial (f-) frontotemporal lobar degeneration (FTLD) patients and asymptomatic family members of f-FTLD patients, characterizing the cohor ... Read more >

Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) to Study Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias (SCA)

Status: Enrolling

Investigator: Andrew Billnitzer

Study Coordinator: Nijah Russell

Phone: 346.238.2287

Spinocerebellar ataxias (SCA) are genetic neurological diseases that cause imbalance, poor coordination, and speech difficulties. There are different kinds of SCA and this study will focus on types 1, 2,3, and 6 (SCA 1, SCA 2, SCA 3 , also known ... Read more >

Clinical Trial Readiness for SCA1 and SCA3

Status: Open Not Enrolling

Investigator: Tetsuo Ashizawa

Study Coordinator: Valerie Flores

Phone: 713.363.9803

The investigators plan to fill the gap between the current state of clinical trial readiness and the optimal one for SCA1 and SCA3, which are fatal rare diseases with no treatments. Through US-European collaborations, the investigators will esta ... Read more >

COMPILATIONS OF CLINICAL FINDINGS IN AMYOTROPHIC LATERAL SCLEROSIS

Status: Open Not Enrolling

Investigator: Stanley Appel

Study Coordinator: Aramide Balogun

Phone: 713.441.6955

The purpose of this protocol is to develop and maintain a clinical findings data bank including diagnostic evaluations obtained from medical records sent from prior medical evaluations, diagnostic intake evaluations and follow-up care in the Met ... Read more >

COVID-19 on the brain

Status: Enrolling

Investigator: Tetsuo Ashizawa

Study Coordinator: Valerie Flores

Phone: 713.363.9803

While solid evidence for direct CNS infection by SARS-CoV-2 is lacking, a consensus has been forming that affected patients are at higher risk of developing neuropsychiatric and neurologic sequelae after overcoming the primary infection, as a co ... Read more >

CREST-2

Status: Enrolling

Investigator: David Chiu

Study Coordinator:

Phone:

Carotid revascularization for primary prevention of stroke (CREST-2) is two independent multicenter, randomized controlled trials of carotid revascularization and intensive medical management versus medical management alone in patients with asym ... Read more >

Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1: END-DM1

Status: Open Not Enrolling

Investigator: Ericka Greene

Study Coordinator: KaDeesia Brown

Phone: 713.441.9120

Provide natural history data, biomarkers, and biological understanding of the phenotypic heterogeneity of myotonic dystrophy type 1 (DM1). ... Read more >

Genomic Translation for ALS Clinical Care

Status: Open Not Enrolling

Investigator: Stanley Appel

Study Coordinator: Sharon Halton

Phone: 713.441.3420

The purpose of the this study to look for abnormal genes and gene expression profiles that help determine why a person develops amyotrophic lateral sclerosis (ALS) and related motor neuron diseases (MND) and why their symptoms present and progre ... Read more >

Global Study of Del-desiran for the Treatment of DM1 (HARBOR)

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Aramide Balogun

Phone: 713.441.6955

The study consists of a Screening Period of up to 6 weeks and 54-week Treatment Period. The anticipated duration is approximately 60 weeks. Participants will be randomized to receive an intravenous infusion of either del-desiran or placebo at ... Read more >

Glutathione and Alzheimer's Disease

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Chimaoge Okafor

Phone: 713.363.7729

Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigat ... Read more >

Glutathione in Mild Cognitive Impairment

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Chimaoge Onyechi

Phone: 713.363.7729

Elderly humans have an increased risk of dementia which begins as mild defects in memory called mild cognitive impairment. Glutathione (GSH), a key endogenous antioxidant has been linked to cognition. This exploratory study will investigate mech ... Read more >

HEALEY ALS Platform Trial

Status: Enrolling

Investigator: Sheetal Shroff

Study Coordinator: Aramide Balogun

Phone: 713.441.6955

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. ... Read more >

HEALEY ALS Platform Trial - Regimen B Verdiperstat

Status: Open Not Enrolling

Investigator: Stanley Appel

Study Coordinator:

Phone:

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen B will evaluate the safety and efficacy of a single study ... Read more >

HEALEY ALS Platform Trial - Regimen C CNM-Au8

Status: Open Not Enrolling

Investigator: Stanley Appel

Study Coordinator: Bing Liao

Phone: 713.363.7310

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen C will evaluate the safety and efficacy of a single study ... Read more >

Houston Alzheimer Disease Study

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Andrea Franco Pando

Phone: 713.441.1150

The purpose of this study is to clarify at the individual level what genes and changes in the body predispose people to Alzheimer’s disease or other dementias. We will measure changes in brain imaging, body fluids, and memory or thinking abiliti ... Read more >

Longitudinal Early-onset Alzheimer's Disease Study Protocol (LEADS)

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Jeffrey Ling

Phone: 713.363.7753

The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, ... Read more >

Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: KaDeesia Brown

Phone: 713.441.9120

Complement component 5 (C5) inhibition therapies have been available for patients with generalized Myasthenia Gravis (gMG) in the United States since the introduction of Soliris® in late 2017. Alexion is developing potential new therapies that ... Read more >

Myotonic Dystrophy Compilation of Clinical Findings

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: KaDeesia Brown

Phone: 713.441.9120

The purpose of this protocol is to make available clinical findings, including blood pressure, pulmonary function tests, cardiac function tests, clinical evaluations, cognitive evaluations, performance tests, medications, routine blood work eval ... Read more >

Neuromuscular Observational Research (MOVR) Data Hub Protocol

Status: Open Not Enrolling

Investigator: Ericka Greene

Study Coordinator: Aramide Balogun

Phone: 713.441.6955

This is a registry of people with neuromuscular diseases. It is the intent to follow patients with ALS and other neuromuscular diseases to determine best practices for care delivery. ... Read more >

not applicable

Status: Open Not Enrolling

Investigator: Kumar Pichumani

Study Coordinator: Kumar Pichumani

Phone: 713.441.7190

Title: Investigation of central nervous system tumor metabolism in patients undergoing surgical resection PI- Kumar Pichumani, PhD coPI- David Baskin, MD Interest in the clinical potential of tumor intermediary metabolism dates to the 19 ... Read more >

NWBT 020221 - DC-Vax

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Helga Jones

Phone: 713.363.9388

" Purpose The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site p ... Read more >

Phase I-II Study Evaluating HSV-tk + Valacyclovir Gene Therapy

Status: Enrolling

Investigator: David Baskin

Study Coordinator: Melissa Daly

Phone: 713.441.3834

NCT03603405 This is a prospective, phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy for anaplastic astrocytoma (AA) or glioblastoma mul ... Read more >

Phase I-II Study Evaluating HSV-tk + Valacyclovir Gene Therapy Combination with Radiotherapy and Chemotherapy for Recurrent Glioblastoma Multiforme

Status: Enrolling

Investigator: David Baskin

Study Coordinator: Melissa Daly

Phone: 713.441.3834

NCT03596086 This is a prospective phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy in recurrent anaplastic astrocytoma or glioblastoma ... Read more >

Protective Genetic Factors Against Neurological Diseases

Status: Open Not Enrolling

Investigator: Jun Li

Study Coordinator: Stephanie Yan Xuan

Phone: 313.217.1098

This study aims to look at the genetic differences between individuals with neurological disorders and healthy controls, and whether these genetic differences contribute to nerve conduction speeds. We expect that this study will identify a small ... Read more >

Role of Brain Inflammation in Alzheimer’s Disease

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Nilene Crisci

Phone: 713.441.3771

The discovery of AD risk genes coding for proteins involved in inflammation has revived the interest in neuroinflammation (or brain inflammation) in the pathogenesis of AD. To understand the role of inflammation in the pathogenesis of AD, it is ... Read more >